Testosterone topical gels — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypogonadism (Male)

• Testosterone topical gels 1%/1.62% (availability varies by program)

What Testosterone topical gels is approved for (FDA label)

Vogelxo is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range.

Source: Read the full FDA label on DailyMed. Label effective date: July 14, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Testosterone topical gels (FDA label)

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions (5.2) and Adverse Reactions (6.2) ] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ] . Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) and Patient Counseling Information (17) ] . WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning Virilization has been reported in children who were secondarily exposed to testosterone gel. ( 5.2 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel. ( 2.2 , 5.2 ) Healthcare providers should advise patients to strictly adhere to recommended instructions for use. ( 2.2 , 5.2 , 17 )

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Testosterone topical gels (FDA label)

Vogelxo (testosterone) gel is a clear to translucent hydroalcoholic topical gel for topical use available in unit-dose tubes, unit-dose packets, and multiple-dose metered pumps. Each tube or packet provides 50 mg testosterone in 5 g of gel. One pump actuation delivers 12.5 mg testosterone in 1.25 g of gel (4 actuations = 50 mg testosterone). Topical Gel available as: 50 mg of testosterone in a unit-dose tube. ( 3 ) 50 mg of testosterone in a unit-dose packet. ( 3 ) 12.5 mg of testosterone per one pump actuation in a metered-dose pump. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Testosterone topical gels (FDA label)

Most common adverse reactions (incidence ≥ 2% of the testosterone gel patients and greater than placebo) are application site reactions and increased hematocrit. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact UPSHER-SMITH LABORATORIES, LLC at 1-855-899-9180 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In a controlled clinical study, 304 patients were treated with testosterone gel 50 mg or 100 mg or placebo gel for up to 90 days.

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Testosterone topical gels (FDA label)

Vogelxo is contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions (5.1) ] . Vogelxo is contraindicated in women who are pregnant. Vogelxo can cause virilization of the female fetus when administered to a pregnant woman. Pregnant women need to be aware of the potential for skin transfer of testosterone from men treated with Vogelxo. If a pregnant woman is exposed to Vogelxo, she should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1 )]. Men with known carcinoma of the breast or known or suspected carcinoma of the prostate. ( 4 , 5.1 ) Women who are pregnant. Testosterone may cause fetal harm. ( 4 , 8.1 )

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Testosterone topical gels (FDA label)

Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH. ( 5.1 ) Avoid unintentional exposure of women or children to Vogelxo. Secondary exposure to testosterone can produce signs of virilization. Vogelxo should be discontinued until the cause of virilization is identified. ( 5.2 ) Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported in patients using testosterone products.

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Testosterone topical gels (FDA label)

Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients. ( 7.1 ) Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of International Normalized Ratio (INR) and prothrombin time is recommended in patients taking warfarin. ( 7.2 ) Use of testosterone with corticosteroids may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal or hepatic disease. ( 7.3 ) 7.1 Insulin Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens.

Source: FDA prescribing information (DailyMed). Set ID: 2dd150f6-cdfd-4d51-8888-12b288f26262. SPL document ID: 39e7ddfb-c092-4cb7-e063-6394a90a1d54. Label effective date: July 14, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.